Under this partnership, BioLeap and Jubilant will integrate BioLeap’s computational fragment based drug design platform with Jubilant’s expertise in chemistry, biology and crystallography to offer a highly competitive preclinical drug development platform.
The partnership will provide customers with integrated preclinical drug discovery services from lead identification and optimization to investigational new drug candidate selection for multiple therapeutic areas.
Gerald Evans, chief business officer of BioLeap, said: “We are delighted to have the opportunity to offer our partners the combined capabilities of Jubilant and BioLeap. This partnership leverages and combines the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development with BioLeap’s edge computational fragment-based design capabilities, to deliver high-quality, cost-effective preclinical drug discovery services.”